Hydroxychloroquine
- Generic Name
- Hydroxychloroquine
- Brand Names
- Plaquenil, Sovuna
- Drug Type
- Small Molecule
- Chemical Formula
- C18H26ClN3O
- CAS Number
- 118-42-3
- Unique Ingredient Identifier
- 4QWG6N8QKH
- Background
Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of quinacrine with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2.
The FDA emergency use authorization for hydroxychloroquine and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.
Hydroxychloroquine was granted FDA approval on 18 April 1955.
A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19.
- Indication
Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.
- Associated Conditions
- Acute Rheumatoid Arthritis, Malaria, Porphyria Cutanea Tarda, Q Fever, Sjogren's Syndrome (SS), Systemic Lupus Erythematosus, Uncomplicated Malaria caused by Plasmodium Vivax, Uncomplicated Malaria caused by Plasmodium malariae, Uncomplicated Malaria caused by Plasmodium ovale, Chronic Discoid Lupus Erythematosus (DLE), Chronic Rheumatoid Arthritis, Uncomplicated Malaria caused by Plasmodium falciparum
The Efficacy and Safety of HCQ Plus Pred in ANA Positive ITP
- Conditions
- Immune Thrombocytopenia With Positive ANA Antibodies
- Interventions
- First Posted Date
- 2024-06-28
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Yunfeng Cheng
- Target Recruit Count
- 129
- Registration Number
- NCT06479304
- Locations
- 🇨🇳
Shanghai Jinshan Hospital, Shanghai, Shanghai, China
🇨🇳Shanghai Zhongshan Hospital, Shanghai, Shanghai, China
🇨🇳Zhongshan Wusong Hospital, Fudan University, Shanghai, Shanghai, China
The Efficacy and Safety of HCQ Plus DEX in ANA Positive ITP
- Conditions
- Immune Thrombocytopenia With Positive ANA Antibodies
- Interventions
- First Posted Date
- 2024-06-28
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Yunfeng Cheng
- Target Recruit Count
- 129
- Registration Number
- NCT06479317
- Locations
- 🇨🇳
Shanghai Zhongshan Hospital, Shanghai, Shanghai, China
🇲🇴University Hospital, Macau University of Science and Technology., Macau, Macau
🇨🇳Zhongshan Qingpu Hospital, Fudan University, Shanghai, Shanghai, China
The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITP
- Conditions
- Immune Thrombocytopenia With Positive ANA Antibodies
- Interventions
- First Posted Date
- 2024-06-28
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Yunfeng Cheng
- Target Recruit Count
- 126
- Registration Number
- NCT06479291
- Locations
- 🇲🇴
Dr. Stanley Ho Medical Foundation, Macau, Macau
🇨🇳Shanghai Jinshan Hospital, Shanghai, Shanghai, China
🇨🇳Wusong Hospital, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Efficacy and Safety of Hydroxychloroquine in the Treatment of Sudden Sensorineural Hearing Loss
- Conditions
- Sudden Hearing Loss
- Interventions
- Drug: Steroid
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Chang Gung Memorial Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT06467526
HCQ in Resectable Localized Prostate Cancer
- Conditions
- Resectable Localized Prostate Cancer
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Lionel.D.Lewis, MD
- Target Recruit Count
- 20
- Registration Number
- NCT06408298
Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study
- Conditions
- IgA Nephropathy
- Interventions
- Drug: Placebo oral tablet
- First Posted Date
- 2024-04-05
- Last Posted Date
- 2025-04-08
- Target Recruit Count
- 334
- Registration Number
- NCT06350630
- Locations
- 🇫🇷
CHU Gabriel Montpied, Clermont-Ferrand, France
🇫🇷Hospices Civils de Lyon, Lyon, France
🇫🇷AP-HM Hôpital de la Conception, Marseille, France
HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer
- Conditions
- Metastatic Breast CancerAdvanced Breast Cancer
- Interventions
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2024-03-25
- Target Recruit Count
- 120
- Registration Number
- NCT06328387
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Hydroxychloroquine in Type 2 Diabetes During Pregnancy
- Conditions
- Type 2 DiabetesDiabetes in Pregnancy
- Interventions
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- National University of Malaysia
- Target Recruit Count
- 56
- Registration Number
- NCT06319560
- Locations
- 🇲🇾
Antenatal clinic, UKM Medical Centre, Cheras, Kuala Lumpur, Malaysia
Hydroxychloroquine May be Beneficial for Preeclampsia
- First Posted Date
- 2023-08-31
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 462
- Registration Number
- NCT06020378
- Locations
- 🇨🇳
Shanghai Jiao Tong University School of Medicine，Renji Hospital, Shanghai, Shanghai, China
The Effects of Hydroxychloroquine in Patients with Inflammatory Cardiomyopathy
- Conditions
- Inflammatory CardiomyopathyMyocarditis
- Interventions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT05961202
- Locations
- 🇨🇳
Tongji Hospital, Wuhan, Hubei, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.